4-Hexylresorcinol pharmaceutical composition for bone disease treatment

The USPTO published a patent application (US20260091001A1) filed December 7, 2025, by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for bone disease prevention and treatment. The application claims ointment formulations and methods of use that demonstrated efficacy in animal models by improving bone thickness, density, and strength through dual mechanisms: promoting osteoblast differentiation and suppressing osteoclast proliferation and differentiation. The application is classified under CPC A61P 19/10 (anti-osteoporosis agents) and lists six inventors including Je-Yong Choi.

Patent applicants and licensees should note this filing when conducting freedom-to-operate analyses for bone disease therapeutics. Competitors developing resorcinol derivatives or osteoporosis treatments should evaluate potential overlap. The assignee may pursue continuation applications or international filings under PCT. No immediate compliance actions are required as patent applications do not create regulatory obligations for third parties.